• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 15, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Heavy Weights and Muscular Dystrophy: New Review Challenges Decades of Exercise Dogma in FSHD

by
October 15, 2026
in Health
Reading Time: 5 mins read
0
Heavy Weights and Muscular Dystrophy: New Review Challenges Decades of Exercise Dogma in FSHD

Heavy Weights and Muscular Dystrophy: New Review Challenges Decades of Exercise Dogma in FSHD

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

For decades, people living with facioscapulohumeral muscular dystrophy (FSHD) have been told to treat the weight room as forbidden territory. Avoid heavy loads, skip eccentric contractions, and if soreness lingers past a day, assume the disease has been provoked. Now, a narrative review published in the Journal of Neurology systematically dismantles this dogma, arguing that the scientific case against high-load resistance training in FSHD was never built on rigorous evidence—and that lifting heavy may, in fact, be one of the most promising low-cost therapies available to this population.

FSHD is among the most common hereditary neuromuscular disorders, affecting roughly 5 in 100,000 people worldwide. Unlike Duchenne muscular dystrophy, it does not shorten life expectancy, but its progressive nature exacts a heavy toll. The disease stems from a genetic error on chromosome 4: a contraction of D4Z4 macrosatellite repeats causes hypomethylation of the region, allowing sporadic expression of DUX4, a transcription factor normally silent in mature skeletal muscle. DUX4 switches on germline and early stem cell genes that should never be active in adult muscle, disrupting cellular homeostasis and triggering inflammation and apoptosis. The result is a progressive, asymmetric loss of muscle mass that typically begins in the face, shoulder girdle, and upper arms, later spreading to the trunk and lower limbs. Severity varies enormously: up to 30 percent of genetic carriers report no symptoms, while approximately 20 percent become wheelchair-dependent.

The pathological picture is more complex than simple muscle wasting. Quantitative MRI reveals fatty infiltration two to three times greater than in age-matched controls, along with STIR hyperintensity lesions—pockets of edema interpreted as signs of active inflammation. Muscle biopsies from STIR-positive regions show mononuclear cell infiltrates, elevated expression of major histocompatibility complex I, and greater collagen deposition, indicating fibrosis. Oxidative stress compounds the damage: transcriptomic analyses show upregulation of TNFα pathway genes, FSHD myoblasts display increased susceptibility to oxidative injury, and patients carry a reduced ratio of reduced to oxidized glutathione in their blood. Critically, these radiological features—fatty infiltration, lesion burden, and shrinking muscle volume—are the most sensitive markers of progression, detectable within a single year, while functional scores often lag behind.

Weakness in FSHD exceeds what muscle loss alone can explain. Individuals consistently show reductions in maximal voluntary contraction force of more than 40 percent compared with controls, and even after correcting for fatty infiltration, specific force—the force per unit of contractile cross-sectional area—remains reduced by over 30 percent. Yet isolated single muscle fibers from the same patients generate nearly normal specific force. This paradox points the finger away from the contractile machinery itself and toward collective impairments: MRI-based estimates of contractile area likely overstate true fiber area because they cannot distinguish fibrosis, edema, and interstitial cells from contractile tissue. Emerging evidence also implicates defective excitation–contraction coupling. Meta-analyses reveal downregulation of genes associated with neuromuscular junction architecture, single-fiber electromyography shows abnormal transmission correlated with disease duration, sarcolemmal reorganization increases the distance between the sarcolemma and the nearest myofibril—potentially disrupting the T-tubule network—and muscle excitability studies reveal partial depolarization of the resting membrane potential, which could inactivate voltage-gated sodium channels and attenuate calcium release from the sarcoplasmic reticulum.

Against this backdrop, the review defines high-load resistance training precisely: programs using loads of 70 to 90 percent of one-repetition maximum, or the 4 to 12 repetition maximum range, which meta-analyses show are most effective at simultaneously increasing muscle mass and maximal strength. The authors emphasize that while lighter loads produce comparable hypertrophy when volume is matched, higher loads yield greater strength gains. Optimal prescription involves at least four sets per muscle group per week—ideally ten or more for maximizing hypertrophy—rest intervals of one to two minutes between sets, a minimum frequency of two weekly bouts, and progressive overload, in which loads are increased over time to maintain the targeted repetition range at near-maximal effort.

The acute responses to such training are well characterized in healthy populations. A single bout causes rapid neuromuscular fatigue, myofibrillar disruption visible under electron microscopy, mild swelling lasting up to 48 hours, soreness persisting for days, and elevated serum creatine kinase. Plasma cytokines such as IL-6, IL-1ra, MCP-1, and G-CSF rise transiently, and severe disruption is followed by mononuclear cell infiltration—collectively termed exercise-induced muscle damage. Crucially, these responses are normal remodeling processes, not signs of intolerance. Healthy individuals recover within days and are protected against comparable damage in subsequent bouts, a phenomenon known as the repeated bout effect. Meanwhile, anabolic signaling through MAPK pathways and mTORC1 drives muscle protein synthesis that remains elevated beyond 48 hours, while protein degradation returns to baseline—the cumulative imbalance producing net accretion of contractile protein.

Long-term, the benefits are substantial. Twelve to 24 weeks of high-load resistance training typically increases one-repetition maximum by 20 to 50 percent, with early gains driven primarily by neural adaptations—increased motor unit recruitment and discharge rate within the first two to four weeks—before morphological hypertrophy of roughly 5 to 20 percent becomes detectable. Strength gains translate into improved gait speed, chair stand performance, and balance, the very capacities that underpin independence. Equally relevant to FSHD, evidence from other populations shows that resistance training reduces fatty infiltration in older and overweight adults, attenuates chronic low-grade inflammation as measured by C-reactive protein, reduces oxidative stress markers in metabolic conditions, and—strikingly—alters inflammatory gene expression and reduces interstitial fibrosis in myositis, an autoimmune myopathy that shares mononuclear infiltration, fatty infiltration, fibrosis, and muscle fiber regeneration with FSHD.

So where did the caution come from? The review traces much of the dogma to two influential studies. Over 50 years ago, Johnson and Braddom reported that most members of an FSHD family were weaker in their dominant arm—the one used habitually—and concluded that extensive use, including resistance training, accelerates disease progression. But the conclusions were never substantiated by statistical analysis, and the methods were described only vaguely. Brouwer and colleagues later found statistically significant side-to-side differences in just 3 of 10 strength tests, with small numerical differences relative to large standard deviations. Subsequent studies across 102 individuals with FSHD found no effect of handedness on weakness patterns, and a case report in monozygotic twins reached the same conclusion. The overwork weakness hypothesis, in other words, does not withstand replication.

The recommendation to avoid loads above 30 percent of one-repetition maximum fares no better. Several resistance training studies have included individuals with FSHD who repeatedly lifted loads well above that threshold, and all reported the training was well tolerated, with most showing moderate improvements in strength and function. On eccentric contractions, the review notes that submaximal eccentric actions—inevitable in daily activities like sitting down—are demonstrably safe, and the only study to test maximal eccentric contractions found that individuals with myopathic disease showed slightly attenuated signs of exercise-induced muscle damage compared with healthy controls, whose creatine kinase rose significantly more three days post-exercise. Though limited to two individuals with FSHD, the study gives no indication of heightened vulnerability. Persistent soreness, the authors add, is the expected response of any untrained person beginning training—not evidence of disease provocation—and clinicians should avoid language that reinforces a sense of fragility, which fuels fear and exercise avoidance.

The most cited study on the topic, published by van der Kooi and colleagues in 2004, trained 19 individuals with FSHD for 52 weeks and is frequently invoked as proof that resistance training offers no benefit. Yet the review highlights critical limitations: the program started with 10RM loads progressing toward 5RM—below the high-load definition—lacked a healthy positive control group, and produced a 37 percent increase in elbow flexion one-repetition maximum that has been overshadowed by emphasis on its negative findings. No available study has adequately addressed whether high-load training affects the major pathological features of FSHD, considered the disease’s inherent asymmetry, or employed gold-standard whole-body MRI to track fibrosis, fatty infiltration, and muscle mass. Until such trials are conducted, the authors conclude, patients and clinicians will remain without answers about an intervention that is accessible, inexpensive, and likely low-risk—one that could delay the mobility decline and loss of independence that define advanced FSHD.

Subject of Research: FSHD

Article Title: High-load resistance training and FSHD: harmful mixture or a silver bullet combination?

Article References: Meinhold, M., & Hornberger, T. A. (2026). High-load resistance training and FSHD: harmful mixture or a silver bullet combination?. Journal of Neurology, 273(10), Article 605. https://doi.org/10.1007/s00415-026-14148-7

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14148-7

Keywords: FSHD, resistance training, muscular dystrophy, exercise science, neuromuscular disorders, DUX4, muscle physiology, High-load, resistance, training, harmful, mixture

News Source: Juliet Wilcox. (October 15, 2026). Heavy Weights and Muscular Dystrophy: New Review Challenges Decades of Exercise Dogma in FSHD. Scienmag.

Tags: DUX4exercise scienceFSHDharmfulHigh-loadmixturemuscle physiologymuscular dystrophyneuromuscular disordersresistanceresistance trainingtraining
Share12Tweet7Share2ShareShareShare1

Related Posts

Years After a Historic EHR Switch, Clinicians Say Workarounds Rule Their Workday

Years After a Historic EHR Switch, Clinicians Say Workarounds Rule Their Workday

October 15, 2026
Peer Review's Quiet Champions: Springer Nature Honors Distinguished Editors of 2026

Peer Review’s Quiet Champions: Springer Nature Honors Distinguished Editors of 2026

October 15, 2026

Community Care Outperforms Usual Treatment in Cutting Schizophrenia Relapse, Review Finds

October 15, 2026

Carbapenem-Resistant Klebsiella pneumoniae Now Infects Half of Clinical Cases in Iran, Landmark Analysis Finds

October 15, 2026

POPULAR NEWS

  • Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    29 shares
    Share 12 Tweet 7
  • Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

    29 shares
    Share 12 Tweet 7
  • Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

    29 shares
    Share 12 Tweet 7
  • New Scale Measures How Ready Nurse Educators Really Are for the AI Era

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.